OSE Immuno

Update on Information Relating to the General Meeting of September 30, 2025

11 Sep 2025 23:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer

11 Sep 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025

09 Sep 2025 11:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025

08 Sep 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation

04 Sep 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation

04 Sep 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM

28 Aug 2025 23:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting

24 Aug 2025 22:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer

20 Aug 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels

17 Jul 2025 09:30:00 By Nasdaq GlobeNewswire

Half-Year Report on Liquidity Contract with Invest Securities

16 Jul 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics met à jour l’information sur les procédures en cours

01 Jul 2025 23:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Publishes Letter to Shareholders

30 Jun 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics provides an update on ongoing proceedings

24 Jun 2025 23:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

20 Jun 2025 10:30:00 By Nasdaq GlobeNewswire

ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025

11 Jun 2025 09:30:00 By Nasdaq GlobeNewswire

UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING

08 Jun 2025 23:00:00 By Nasdaq GlobeNewswire

Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025

03 Jun 2025 23:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology

03 Jun 2025 23:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer

02 Jun 2025 09:00:00 By Nasdaq GlobeNewswire